A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer

Lapatinib is approved in combination with capecitabine for treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) who have progressed on prior trastuzumab in the metastatic setting. Vinorelbine is an important chemotherapy option for MBC. W...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Janni, Wolfgang, Sarosiek, Tomasz, Karaszewska, Boguslawa, Pikiel, Joanna, Staroslawska, Elzbieta, Potemski, Piotr, Salat, Christoph, Brain, Etienne, Caglevic, Christian, Briggs, Kathryn, DeSilvio, Michelle, Marini, Luca, Papadimitriou, Christos
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2014
Assuntos:
Clinical Trial
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3907671/
https://ncbi.nlm.nih.gov/pubmed/24402830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2828-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados